Merck & Co., Inc. (MRK) News Today

Merck & Co., Inc. (NYSE: MRK) is trading near its 52-week high, supported by strong confidence in Keytruda and the company’s longer-term pipeline. However, investors remain focused on execution, valuation, and the expected 2028 Keytruda patent cliff. Recent coverage is generally constructive, although most items do not represent material new financial disclosures.

• Positive Sentiment: Guggenheim raised its price target to $170 from $146 and reaffirmed a “Buy” rating. The new target implies meaningful upside from the referenced trading level and provides a positive near-term analyst catalyst. Guggenheim raises Merck price target
• Positive Sentiment: Keytruda remains the primary growth engine. Analysts point to continued demand for the cancer drug, while Merck’s pipeline and newer products could help offset the eventual loss of exclusivity expected later this decade. Merck trading near 52-week high
• Positive Sentiment: Merck will present at Morgan Stanley’s 24th Annual Global Healthcare Conference. The event could give investors additional insight into Keytruda demand, the pipeline, new product launches, and plans to manage the 2028 patent cliff. Merck to participate in Morgan Stanley healthcare conference
• Neutral Sentiment: Industry reports identify additional market opportunities. Merck is listed among participants in the growing pulmonary arterial hypertension and global vaccines markets, but the reports contain no specific Merck sales, trial, or product announcements. Pulmonary arterial hypertension market report
• Negative Sentiment: Investors are still weighing valuation and patent risk. With MRK near its 52-week high, expectations are elevated, while the eventual Keytruda patent expiration remains a major long-term concern despite progress in replacing lost revenue. Merck and GARDASIL outlook